Managing uncontrolled hemorrhage in trauma and surgery: A novel and promising approach

Canadian Journal of Anesthesia

Volumn 49, Issue 10, 2002, Pages

  Hardy, Jean François ^a  

^a NOTRE DAME HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN; HEMOGLOBIN; HEMOSTATIC AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; WARFARIN;

ANESTHESIST; ARTICLE; BLEEDING DISORDER; BLOOD CLOTTING; BRAIN HEMORRHAGE; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ERYTHROCYTE; FIBRINOLYSIS; HEART SURGERY; HEMOPHILIA; HUMAN; INJURY; LIVER TRANSPLANTATION; METABOLIC ACIDOSIS; PRIORITY JOURNAL; SURGICAL TECHNIQUE; THROMBOCYTE COUNT; THROMBOSIS; TREATMENT PLANNING;

FACTOR VII; HEMORRHAGE; HEMOSTASIS, SURGICAL; HEMOSTATICS; HUMANS; RECOMBINANT PROTEINS; WOUNDS AND INJURIES;

EID: 0037003551     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Hedner U. Recombinant activated factor VII as a universal haemostatic agent. Blood Coagul Fibrinolysis 1998; 9(Suppl 1): S147-52.
2. Hedner U. NovoSeven as a universal haemostatic agent. Blood Coagul Fibrinolysis 2000; 11 (Suppl 1): S107-11.
3. Ingerslev J. Hemophilia. Strategies for the treatment of inhibitor patients. Haematologica 2000; 85 (10 Suppl): 15-20.
4. Negrier C, Lienhart A. Overall experience with NovoSeven. Blood Coagul Fibrinolysis 2000; 11 (Suppl 1): S19-24.
5. Kenet G, Lubetsky A, Gitel S, Luboshitz J, Varon D, Martinowitz U. Treatment of bleeding episodes in patients with hemophilia and an inhibitor: comparison of two treatment protocols with recombinant activated factor VII. Blood Coagul Fibrinolysis 2000; 11 (Suppl 1): S35-8.
6. Franchini M, Capra F, Capelli C, de Maria E, Lippi G, Gandini G. Clinical efficacy of recombinant activated factor VII (rFVIIa) during acute bleeding episode and surgery in a patient with acquired hemophilia A with high inhibitor titer. Haematologica 2001; 86: E12.
7. Arkin S, Cooper HA, Hutter JJ, et al. Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors. Results of the novoseven emergency-use program. Haemostasis 1998; 28: 93-8.
8. Goudemand J. Recombinant activated factor VII: a new treatment for hemophilia. Transfus Clin Biol 1998; 5: 260-5.
9. Papadaki HA, Xylouri I, Valatas W, Petinarakis J, Kontopoulou I, Eliopoulos GD. Severe acquired hemophilia A successfully treated with activated recombinant human factor VII. Ann Hematol 1998; 77: 123-5.
10. Schmidt ML, Gamerman S, Smith HE, Scott JP, DiMichele DM. Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia A patients with inhibitors. Am J Hematol 1994; 47: 36-40.
11. O'Marcaigh AS, Schmalz BJ, Shaughnessy WJ, Gilchrist GS. Successful hemostasis during a major orthopedic operation by using recombinant activated factor VII in a patient with severe hemophilia A and a potent inhibitor. Mayo Clin Proc 1994; 69: 641-4.
12. Martinowitz U, Kenet G, Segal E, et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001; 51: 431-8; discussion 438-9.
13. Martinowitz U, Holcomb JB, Pusateri AE, et al. Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries. J Trauma 2001; 50: 721-9.
14. Murkin JM. A novel hemostatic agent: the potential role of recombinant activated factor VII (rFVIIa) in anesthetic practice. Can J Anesth 2002; 49 (Suppl 2): S21-S26.
15. Martinowitz U, Kenet G, Lubetski A, Luboshitz J, Segal E. Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma. Can J Anesth 2002; 49 (Suppl 2): S15-S20.
16. Quaknine-Orlando B, Samama CM, Riou B, et al. Role of the hematocrit in a rabbit model of arterial thrombosis and bleeding. Anesthesiology 1999; 90: 1454-61.
17. Escolar G, Garrido M, Mazzara R, Castillo R, Ordinas A. Experimental basis for the use of red cell transfusion in the management of anemic-thrombocytopenic patients. Transfusion 1988; 28: 406-11.
18. Santos MT, Valles J, Marcus AJ, et al. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. A new approach to platelet activation and recruitment. J Clin Invest 1991; 87: 571-80.
19. Santos MT, Valles J, Aznar J, Marcus AJ, Broekman MJ, Safier LB. Prothrombotic effects of erythrocytes on platelet reactivity. Reduction by aspirin. Circulation 1997; 95: 63-8.
20. Dietrich W, Spannagl M. Caveat against the use of activated recombinant factor VII for intractable bleeding in cardiac surgery. Anesth Analg 2002; 94: 1369-70; discussion 1370-1.
21. Green D. Complications associated with the treatment of haemophiliacs with inhibitors. Haemophilia 1999; 5 (Suppl 3): 11-7.
22. Schulman S. Safety, efficacy and lessons from continuous infusion with rFVIIa. rFVIIa-CI Group. Haemophilia 1998; 4: 564-7.
23. Roberts HR. Clinical experience with activated factor VII: focus on safety aspects. Blood Coagul Fibrinolysis 1998; 9 (Suppl 1): S115-8.
24. Allen GA, Hoffman M, Roberts HR, Monroe DM III. Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage. Can J Anesth 2002; 49 (Suppl 2): S7-S14.